This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Larder, B. A. Articles by St. Clair, M. H. Search for Related Content PubMed PubMed Citation Articles by Larder, B. A. Articles by St. Clair, M. H.

 Previous Article  |  Next Article 

J. Virol., 09 1996, 5922-5929, Vol 70, No. 9
Copyright © 1996, American Society for Microbiology

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'- dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group

BA Larder, A Kohli, S Bloor, SD Kemp, PR Harrigan, RT Schooley, JM Lange, KN Pennington and MH St. Clair
Glaxo Wellcome Research and Development, Stevenage, Hertfordshire, United Kingdom.

Human immunodeficiency virus type 1 (HIV-1) isolates obtained prior to and during a combination therapy trial comparing zidovudine (AZT; 3'- azidothymidine) monotherapy with AZT plus 2',3'-dideoxyinosine (ddI) or AZT plus 2',3'-dideoxycytidine (ddC) were assessed for the development of drug resistance. Drug susceptibility was measured by using two different phenotypic assays, one that requires infection of peripheral blood mononuclear cells with HIV-1 isolated from cocultures and a second based on infection of HeLa CD4+ cells with recombinant virus containing the reverse transcriptase (RT) of the clinical isolate. In addition, genotypic assessment of resistance was obtained by DNA sequencing of the RT coding region. No difference in the development of AZT resistance was noted in isolates from individuals receiving AZT monotherapy or combination therapy. However, a low frequency of ddI or ddC resistance was seen in isolates from the combination arms, which may at least partially explain the enhanced efficacy observed with these drug combinations compared with monotherapy. It was noted from DNA sequencing that a relatively high frequency of the nonnucleoside RT inhibitor resistance mutation, codon 181 changed from encoding Tyr to encoding Cys, was present in some isolates both before and during nucleoside analog combination therapy. Since these patients were unlikely to have access to nonnucleoside RT inhibitors, it is probable that this mutation preexisted at a reasonable level in the wild-type virus population. Comparisons of the AZT susceptibility assays indicated a good correlation between the phenotypic and genotypic determinations. However, direct numerical comparisons between the phenotypic assays were not reliable, suggesting that valid comparisons of different resistance data sets will require the use of the same assay procedure.

This article has been cited by other articles:

• Wainberg, M. A., Brenner, B. G., Turner, D. (2005). Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 49: 1671-1678 [Full Text]  
• Sturmer, M., Staszewski, S., Doerr, H.-W., Larder, B., Bloor, S., Hertogs, K. (2003). Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214. Antimicrob. Agents Chemother. 47: 54-61 [Abstract] [Full Text]  
• Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
• Sato, H., Tomita, Y., Shibamura, K., Shiino, T., Miyakuni, T., Takebe, Y. (2000). Convergent Evolution of Reverse Transcriptase (RT) Genes of Human Immunodeficiency Virus Type 1 Subtypes E and B following Nucleoside Analogue RT Inhibitor Therapies. J. Virol. 74: 5357-5362 [Abstract] [Full Text]  
• Imamichi, T., Sinha, T., Imamichi, H., Zhang, Y.-M., Metcalf, J. A., Falloon, J., Lane, H. C. (2000). High-Level Resistance to 3'-Azido-3'-Deoxythimidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1. J. Virol. 74: 1023-1028 [Abstract] [Full Text]  
• Miller, V., de Béthune, M.-P., Kober, A., Stürmer, M., Hertogs, K., Pauwels, R., Stoffels, P., Staszewski, S. (1998). Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride. Antimicrob. Agents Chemother. 42: 3123-3129 [Abstract] [Full Text]  
• Kaul, S., Christofalo, B., Raymond, R. H., Stewart, M. B., Macleod, C. M. (1998). Effect of Food on the Bioavailability of Stavudine in Subjects with Human Immunodeficiency Virus Infection. Antimicrob. Agents Chemother. 42: 2295-2298 [Abstract] [Full Text]  
• Serio, D., Rizvi, T. A., Cartas, M., Kalyanaraman, V. S., Weber, I. T., Koprowski, H., Srinivasan, A. (1997). Development of a novel anti-HIV-1 agent from within: Effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc. Natl. Acad. Sci. USA 94: 3346-3351 [Abstract] [Full Text]